GlaxoSmithKline is investing $100 million in its manufacturing site in Hamilton, MT to expand the production capacity of key components of the adjuvant system used in several of GSK’s vaccines, including SHINGRIX, which was approved by the U.S. FDA in October 2017. The Hamilton vaccines facility currently manufactures components of GSK’s essential adjuvant technologies, which this investment will expand further. GSK’s adjuvant systems help achieve a stronger immune response. &#...